New cancer drug copycat tested in healthy people

NCT ID NCT03881787

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called CDP1, which is a close copy of the cancer drug Erbitux, in 84 healthy male volunteers. The goal was to see how the body handles CDP1, whether it causes side effects, and if it triggers an immune response. The results will help decide if CDP1 can move into larger studies in cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

anti-EGFR monoclonal antibody (CDP1)

What this could lead to

If successful, this could support CDP1 as a more affordable alternative to Erbitux for treating certain cancers.

What could go wrong

This is an early-phase trial in healthy people, not patients. It only checks safety and drug levels, not whether it works against cancer. The drug may still fail in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

  • West China Hospital

    Chengdu, Sichuang, China